Tumor necrosis factor receptor associated factor-4: An adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a

Ahmed,Fozia; Shiraishi,Takumi; Vessella,Robert   L.; Kulkarni,Prakash

doi:10.3892/or.2013.2789

Tumor necrosis factor receptor associated factor-4: An adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a

Authors:
- Fozia Ahmed
- Takumi Shiraishi
- Robert L. Vessella
- Prakash Kulkarni
View Affiliations

Affiliations: James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA, Department of Urology, University of Washington, Seattle, Wa 98104, USA
Published online on: October 8, 2013 https://doi.org/10.3892/or.2013.2789
Pages: 2963-2968

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor necrosis factor receptor (TNFR)-associated factor 4 (TRAF4) is a member of TRAF family proteins that act as major signal transducers of the TNF receptor and the interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) superfamily. TRAF4 has been reported to be overexpressed in various human cancers. However, the exact mechanisms that regulate the expression of TRAF4 still remain elusive. The objective of the present study was to investigate the regulatory mechanism of TRAF4 expression in prostate cancer. We initially identified microRNA-29a (miR‑29a) as a possible candidate to bind TRAF4 3' untranslated region (3'UTR) by the algorithm, TargetScan. The expression of TRAF4 mRNA and protein was inversely associated with miR-29a expression in prostate cancer cell lines (LNCaP, DU145 and PC3). TRAF4 expression was reduced by the introduction of mimic miR-29a in LNCaP cells. Luciferase activity from the construct harboring wild-type TRAF4 3'UTR was reduced by the mimic miR-29a and this reduction was diminished by introducing mutations at the predicted miR-29a binding site. On the other hand, TRAF4 was upregulated when transfected with the inhibitor of miR-29a in DU145 and PC3 cells. TRAF4 was significantly upregulated in patients with metastatic prostate cancer compared to those with localized prostate cancer. Furthermore, there was a significant inverse correlation between TRAF4 and miR-29a expression in tumor tissues from radical prostatectomy. Considered together, our results suggest that the tumor suppressor microRNA, miR-29a, is one of the regulators of TRAF4 expression in metastatic prostate cancer.

View Figures

View References

1	Chung JY, Park YC, Ye H and Wu H: All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 115:679–688. 2002.PubMed/NCBI
2	Rothe M, Wong SC, Henzel WJ and Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 78:681–692. 1994. View Article : Google Scholar : PubMed/NCBI
3	Xie P: TRAF molecules in cell signaling and in human diseases. J Mol Signal. 8:72013. View Article : Google Scholar : PubMed/NCBI
4	Regnier CH, Tomasetto C, Moog-Lutz C, et al: Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem. 270:25715–25721. 1995. View Article : Google Scholar
5	Camilleri-Broet S, Cremer I, Marmey B, et al: TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene. 26:142–147. 2007. View Article : Google Scholar : PubMed/NCBI
6	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
7	Dews M, Homayouni A, Yu D, et al: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 38:1060–1065. 2006. View Article : Google Scholar : PubMed/NCBI
8	El Baroudi M, Cora D, Bosia C, Osella M and Caselle M: A curated database of miRNA mediated feed-forward loops involving MYC as master regulator. PLoS One. 6:e147422011.PubMed/NCBI
9	Hermeking H: p53 enters the microRNA world. Cancer Cell. 12:414–418. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
11	Kole AJ, Swahari V, Hammond SM and Deshmukh M: miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev. 25:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
12	Park SY, Lee JH, Ha M, Nam JW and Kim VN: miR-29 miRNAs activate p53 by targeting p85 α and CDC42. Nat Struct Mol Biol. 16:23–29. 2009.PubMed/NCBI
13	Fabbri M, Garzon R, Cimmino A, et al: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 104:15805–15810. 2007. View Article : Google Scholar : PubMed/NCBI
14	Garzon R, Heaphy CE, Havelange V, et al: MicroRNA 29b functions in acute myeloid leukemia. Blood. 114:5331–5341. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sengupta S, den Boon JA, Chen IH, et al: MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA. 105:5874–5878. 2008. View Article : Google Scholar : PubMed/NCBI
17	Xiong Y, Fang JH, Yun JP, et al: Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 51:836–845. 2010.PubMed/NCBI
18	Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
20	Shiraishi T, Terada N, Zeng Y, et al: Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med. 9:1532011. View Article : Google Scholar : PubMed/NCBI
21	Yoshida T, Shiraishi T, Horinaka M, et al: Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci. 98:1417–1423. 2007. View Article : Google Scholar
22	Kedinger V and Rio MC: TRAF4, the unique family member. Adv Exp Med Biol. 597:60–71. 2007. View Article : Google Scholar : PubMed/NCBI
23	Kalkan T, Iwasaki Y, Park CY and Thomsen GH: Tumor necrosis factor-receptor-associated factor-4 is a positive regulator of transforming growth factor-β signaling that affects neural crest formation. Mol Biol Cell. 20:3436–3450. 2009.PubMed/NCBI
24	Ye L, Lewis-Russell JM, Kyanaston HG and Jiang WG: Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol. 22:1129–1147. 2007.PubMed/NCBI
25	Bubendorf L, Schopfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
26	Chang TC, Yu D, Lee YS, et al: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
27	Ellwood-Yen K, Graeber TG, Wongvipat J, et al: Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 4:223–238. 2003. View Article : Google Scholar : PubMed/NCBI
28	Hawksworth D, Ravindranath L, Chen Y, et al: Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis. 13:311–315. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jenkins RB, Qian J, Lieber MM and Bostwick DG: Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57:524–531. 1997.PubMed/NCBI
30	Karin M: Nuclear factor-κB in cancer development and progression. Nature. 441:431–436. 2006.
31	Ismail HA, Lessard L, Mes-Masson AM and Saad F: Expression of NF-κB in prostate cancer lymph node metastases. Prostate. 58:308–313. 2004.
32	Lessard L, Begin LR, Gleave ME, Mes-Masson AM and Saad F: Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 93:1019–1023. 2005. View Article : Google Scholar : PubMed/NCBI
33	Lessard L, Karakiewicz PI, Bellon-Gagnon P, et al: Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res. 12:5741–5745. 2006. View Article : Google Scholar : PubMed/NCBI
34	Setlur SR, Royce TE, Sboner A, et al: Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res. 67:10296–10303. 2007. View Article : Google Scholar : PubMed/NCBI
35	Esparza EM and Arch RH: TRAF4 functions as an intermediate of GITR-induced NF-kappaB activation. Cell Mol Life Sci. 61:3087–3092. 2004. View Article : Google Scholar : PubMed/NCBI